While the U.S. health care system is notoriously costly, prices of generic drugs have actually been falling. Price spikes like EpiPen’s reflect a lack of competition that can be curbed by allowing generics approved abroad to be sold in the U.S., Greg Ip writes.
from WSJ.com: US Business http://ift.tt/2c8PtOq
via IFTTT
No comments:
Post a Comment